Comparison of Helicobacter pylori Eradication Rates of 2-week Levofloxacin Containing Triple Therapy, Levofloxacin Containing Bismuth Quadruple Therapy and Standard Bismuth Quadruple Therapy as a First-line Regimen

Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin containing triple therapy, levofloxacin containing bismuth quadruple therapy and standard bismuth containing quadruple therapy as a first-line regimen for eradication of Helicobacter pylori (H pylori). Methods: A total of 329 patients with H pylori infection were randomly divided into three groups to receive: a) levofloxacin containing bismuth quadruple therapy, RBAL (rabeprazole 20 mg b.i.d., bismuth subsalicylate 562 mg b.i.d., amoxicillin 1 gr b.i.d, levofloxacin 500 mg once daily), b) standard bismuth quadruple therapy, RBMT (rabeprazole 20 mg b.i.d, subsalicylate 562 mg b.i.d., metronidazole 500 mg t.i.d, tetracycline 500 mg q.i.d), c) levofloxacin containing triple therapy, RAL (rabeprazole 20 mg b.i.d., amoxicillin 1 gr b.i.d, levofloxacin 500 mg once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per-protocol (PP) analysis. Results: The eradication rates of the above three groups using ITT analysis were RBAL: 83.8%; RBMT: (88.3% ) and using PP analysis RAL: (74.8%) RBAL: (91.2%), RBMT: (92.5% ), and RAL: (79.2%). The eradication rate using RBMT was significantly higher than that of RAL (p=0.029 in ITT analysis and p=0.017 in PP analysis). Several side effects occurred in 156(54.1%) in RBAL group, 215(52.3%) in RBMT group and 56(26.2 %) in RAL group (p>0.05 between RBAL and RBMT, p
Source: Medical Principles and Practice - Category: Internal Medicine Source Type: research